Design of Hedgehog pathway inhibitors for cancer treatment

Jitender Bariwal, Virender Kumar, Yuxiang Dong, Ram I Mahato

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Hedgehog (Hh) signaling is involved in the initiation and progression of various cancers and is essential for embryonic and postnatal development. This pathway remains in the quiescent state in adult tissues but gets activated upon inflammation and injuries. Inhibition of Hh signaling pathway using natural and synthetic compounds has provided an attractive approach for treating cancer and inflammatory diseases. While the majority of Hh pathway inhibitors target the transmembrane protein Smoothened (SMO), some small molecules that target the signaling cascade downstream of SMO are of particular interest. Substantial efforts are being made to develop new molecules targeting various components of the Hh signaling pathway. Here, we have discussed the discovery of small molecules as Hh inhibitors from the diverse chemical background. Also, some of the recently identified natural products have been included as a separate section. Extensive structure-activity relationship (SAR) of each chemical class is the focus of this review. Also, clinically advanced molecules are discussed from the last 5 to 7 years. Nanomedicine-based delivery approaches for Hh pathway inhibitors are also discussed concisely.

Original languageEnglish (US)
Pages (from-to)1137-1204
Number of pages68
JournalMedicinal Research Reviews
Volume39
Issue number3
DOIs
StatePublished - May 2019

Fingerprint

Nanomedicine
Structure-Activity Relationship
Biological Products
Embryonic Development
Neoplasms
Inflammation
Wounds and Injuries
Smoothened Receptor

Keywords

  • GDC-0449
  • Hedgehog inhibitor
  • SMO
  • Smoothened
  • cancer
  • cyclopamine
  • nanomedicine
  • structure-activity relationship (SAR)

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Design of Hedgehog pathway inhibitors for cancer treatment. / Bariwal, Jitender; Kumar, Virender; Dong, Yuxiang; Mahato, Ram I.

In: Medicinal Research Reviews, Vol. 39, No. 3, 05.2019, p. 1137-1204.

Research output: Contribution to journalReview article

Bariwal, Jitender ; Kumar, Virender ; Dong, Yuxiang ; Mahato, Ram I. / Design of Hedgehog pathway inhibitors for cancer treatment. In: Medicinal Research Reviews. 2019 ; Vol. 39, No. 3. pp. 1137-1204.
@article{fe6e532afe7f45e48295759acda07fe3,
title = "Design of Hedgehog pathway inhibitors for cancer treatment",
abstract = "Hedgehog (Hh) signaling is involved in the initiation and progression of various cancers and is essential for embryonic and postnatal development. This pathway remains in the quiescent state in adult tissues but gets activated upon inflammation and injuries. Inhibition of Hh signaling pathway using natural and synthetic compounds has provided an attractive approach for treating cancer and inflammatory diseases. While the majority of Hh pathway inhibitors target the transmembrane protein Smoothened (SMO), some small molecules that target the signaling cascade downstream of SMO are of particular interest. Substantial efforts are being made to develop new molecules targeting various components of the Hh signaling pathway. Here, we have discussed the discovery of small molecules as Hh inhibitors from the diverse chemical background. Also, some of the recently identified natural products have been included as a separate section. Extensive structure-activity relationship (SAR) of each chemical class is the focus of this review. Also, clinically advanced molecules are discussed from the last 5 to 7 years. Nanomedicine-based delivery approaches for Hh pathway inhibitors are also discussed concisely.",
keywords = "GDC-0449, Hedgehog inhibitor, SMO, Smoothened, cancer, cyclopamine, nanomedicine, structure-activity relationship (SAR)",
author = "Jitender Bariwal and Virender Kumar and Yuxiang Dong and Mahato, {Ram I}",
year = "2019",
month = "5",
doi = "10.1002/med.21555",
language = "English (US)",
volume = "39",
pages = "1137--1204",
journal = "Medicinal Research Reviews",
issn = "0198-6325",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Design of Hedgehog pathway inhibitors for cancer treatment

AU - Bariwal, Jitender

AU - Kumar, Virender

AU - Dong, Yuxiang

AU - Mahato, Ram I

PY - 2019/5

Y1 - 2019/5

N2 - Hedgehog (Hh) signaling is involved in the initiation and progression of various cancers and is essential for embryonic and postnatal development. This pathway remains in the quiescent state in adult tissues but gets activated upon inflammation and injuries. Inhibition of Hh signaling pathway using natural and synthetic compounds has provided an attractive approach for treating cancer and inflammatory diseases. While the majority of Hh pathway inhibitors target the transmembrane protein Smoothened (SMO), some small molecules that target the signaling cascade downstream of SMO are of particular interest. Substantial efforts are being made to develop new molecules targeting various components of the Hh signaling pathway. Here, we have discussed the discovery of small molecules as Hh inhibitors from the diverse chemical background. Also, some of the recently identified natural products have been included as a separate section. Extensive structure-activity relationship (SAR) of each chemical class is the focus of this review. Also, clinically advanced molecules are discussed from the last 5 to 7 years. Nanomedicine-based delivery approaches for Hh pathway inhibitors are also discussed concisely.

AB - Hedgehog (Hh) signaling is involved in the initiation and progression of various cancers and is essential for embryonic and postnatal development. This pathway remains in the quiescent state in adult tissues but gets activated upon inflammation and injuries. Inhibition of Hh signaling pathway using natural and synthetic compounds has provided an attractive approach for treating cancer and inflammatory diseases. While the majority of Hh pathway inhibitors target the transmembrane protein Smoothened (SMO), some small molecules that target the signaling cascade downstream of SMO are of particular interest. Substantial efforts are being made to develop new molecules targeting various components of the Hh signaling pathway. Here, we have discussed the discovery of small molecules as Hh inhibitors from the diverse chemical background. Also, some of the recently identified natural products have been included as a separate section. Extensive structure-activity relationship (SAR) of each chemical class is the focus of this review. Also, clinically advanced molecules are discussed from the last 5 to 7 years. Nanomedicine-based delivery approaches for Hh pathway inhibitors are also discussed concisely.

KW - GDC-0449

KW - Hedgehog inhibitor

KW - SMO

KW - Smoothened

KW - cancer

KW - cyclopamine

KW - nanomedicine

KW - structure-activity relationship (SAR)

UR - http://www.scopus.com/inward/record.url?scp=85057800650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057800650&partnerID=8YFLogxK

U2 - 10.1002/med.21555

DO - 10.1002/med.21555

M3 - Review article

C2 - 30484872

AN - SCOPUS:85057800650

VL - 39

SP - 1137

EP - 1204

JO - Medicinal Research Reviews

JF - Medicinal Research Reviews

SN - 0198-6325

IS - 3

ER -